Full Press Release Details
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates.
LXRX
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Key Takeaway: Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Price reaction · baseline $1.6 (2026-05-06 close) · hit after-hours · 1 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus